On this page
Quick Reference
Overview and Recommendations
Background
- •Pulmonary embolism (PE), obstruction of the pulmonary arteries by thrombus, usually from lower-extremity deep veins, is the third most frequent cardiovascular emergency worldwide and a leading cause of maternal mortality in the developed world, with an estimated 60,000-100,000 deaths annually in the United States alone.
- •The paradigm for acute PE management shifted from a one-size-fits-all approach (heparin → warfarin) to a risk-stratified model driven by the 2014 ESC algorithm and the 2016 CHEST guideline, which established DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) as first-line over vitamin K antagonists, a change supported by the landmark EINSTEIN-PE, Hokusai-VTE, and AMPLIFY trials, which collectively showed comparable efficacy with 40-50% less major bleeding.
- •The central pathophysiology is acute right ventricular (RV) pressure overload from mechanical obstruction and neurohumoral vasoconstriction (thromboxane A₂, serotonin). A thin-walled RV poorly adapted to sudden afterload dilates, becomes ischemic, and fails, the hallmark of high-risk (massive) PE. In a subset of patients, failure of clot lysis leads to chronic thromboembolic pulmonary hypertension (CTEPH), driven by plasmin-resistant fibrin and a macrophage-driven inflammatory milieu.
- •PE is classified by clinical severity: high-risk (sustained hypotension SBP <90 mmHg for ≥15 min or requiring vasopressors), intermediate-risk (normotensive but with RV dysfunction on imaging or elevated cardiac biomarkers), and low-risk (no RV strain, normal biomarkers). The 30-day mortality ranges from <1% in low-risk patients managed as outpatients to 30-50% in high-risk PE with shock.
Evaluation
- •Suspect PE in any patient with acute dyspnea, pleuritic chest pain, hemoptysis, or syncope, especially when accompanied by risk factors such as recent surgery, immobilization, cancer, pregnancy, or prior VTE.
- •Assess pre-test probability using a validated tool, the simplified single-question approach ('Is PE the most likely diagnosis?') is as effective as the or and allows a higher D-dimer threshold of 1000 ng/mL when PE is not the most likely diagnosis.
- •Order a high-sensitivity assay in patients with low or moderate pre-test probability. Use age-adjusted thresholds: for age ≥50 years, the upper limit of normal is age × 10 ng/mL (e.g., 700 ng/mL at 70 years). A negative D-dimer rules out PE with a 3-month failure rate <0.5%.
- •If D-dimer is positive or pre-test probability is high, proceed to (CTPA), the gold standard. CTPA identifies PE in ~20% of suspected patients, and a negative CTPA rules out PE with a 3-month VTE risk of 0.0% (level 1 evidence).
- •Use as an alternative when CTPA is contraindicated (severe contrast allergy, renal impairment, pregnancy) or in young women to reduce breast radiation. Planar V/Q has a negative predictive value >99% when interpreted as normal or low probability.
- •In pregnancy, apply the pregnancy-adapted : evaluate three clinical criteria (clinical signs of DVT, hemoptysis, PE as most likely diagnosis). If 0 criteria, use D-dimer threshold of 1000 ng/mL; if ≥1 criteria, use 500 ng/mL. This approach avoided CTPA in 39% of pregnant women (65% in the first trimester) with a 0.21% 3-month VTE failure rate.
- •Perform point-of-care ultrasound as a supplementary tool: a normal anterior lung profile plus evidence of DVT on compression ultrasound has 99% specificity for PE, but sensitivity is low (81%). A negative ultrasound does not rule out PE.
- •Once PE is confirmed, immediately stratify risk using the . Score 1 point each for age >80 years, cancer, chronic cardiopulmonary disease, heart rate ≥110 bpm, SBP <100 mmHg, and SpO₂ <90%. A score of 0 identifies low-risk patients with ~1% 30-day mortality.
- •Order cardiac biomarkers: high-sensitivity troponin (elevated in ~50% of PE patients) and NT-proBNP or BNP. Elevated BNP increases the odds of a complicated in-hospital course 6.8-fold (95% CI 4.4-10) and 30-day mortality 7.6-fold (95% CI 3.4-17). Use age-adjusted hsTnT: ≥14 pg/mL for age <75 years, ≥45 pg/mL for age ≥75 years.
- •Obtain echocardiography or CT to assess RV function. RV dilation on CT (RV/LV ratio >1.0) increases 30-day mortality 2.08-fold (95% CI 1.63-2.66) and PE-related death 7.35-fold (95% CI 3.59-15.09). Echocardiographic signs of RV dysfunction (e.g., TAPSE <16 mm, McConnell's sign) further refine risk.
- •Use the to select low-risk patients for outpatient management. The 11-item checklist includes hemodynamic instability, need for oxygen, active bleeding, severe renal impairment, and other comorbidities. If all criteria are negative, direct discharge is safe (30-day adverse outcome rate 1.1% in a randomized trial).
Management
- •Initiate anticoagulation immediately once PE is confirmed and no contraindications exist. For most patients, start a direct oral anticoagulant (DOAC) without a parenteral lead-in.
- •First-line: 10 mg orally twice daily for 7 days, then 5 mg twice daily for at least 3 months. In the COBRRA trial, apixaban caused significantly less clinically relevant bleeding than rivaroxaban (3.3% vs 7.1%; RR 0.46; NNT=27).
- •Alternative: 15 mg orally twice daily for 21 days, then 20 mg once daily. Acceptable for patients who prefer once-daily dosing, but bleeding risk is higher than with apixaban.
- •Alternative: 60 mg once daily after 5 days of parenteral anticoagulation (LMWH or UFH). Reduce to 30 mg once daily if CrCl 15-50 mL/min or body weight ≤60 kg.
- •For patients with cancer-associated VTE, apixaban and edoxaban are preferred over LMWH. Apixaban is noninferior to dalteparin (HR 0.63 for recurrence) with similar major bleeding (3.8% vs 4.0%). After 6 months of full-dose therapy, consider reduced-dose apixaban 2.5 mg twice daily for extended secondary prevention (noninferior to 5 mg twice daily with fewer bleeding events).
- •For high-risk (massive) PE with sustained hypotension (SBP <90 mmHg for ≥15 min or requiring vasopressors), administer immediate systemic fibrinolysis: as a single weight-based IV bolus (30-50 mg). This reduces death or hemodynamic decompensation from 5.6% to 2.6% (NNT=34) but increases major bleeding from 1.2% to 6.3% (NNH=20).
- •For intermediate-risk PE (normotensive with RV dysfunction and elevated troponin) who develop cardiorespiratory distress (SBP ≤110 mmHg, heart rate ≥100 bpm, respiratory rate >20), consider ultrasound-facilitated catheter-directed fibrinolysis (UF-CDT) with alteplase. This reduces the composite of PE-related death, decompensation, or recurrence from 10.3% to 4.0% (RR 0.39; NNT=16) without excess intracranial hemorrhage.
- •Provide supplemental oxygen to maintain SpO₂ ≥90% (≥92% in chronic lung disease). Do not give routine oxygen to normoxemic intermediate-risk patients, it does not improve RV recovery and may mask clinical deterioration.
- •For hypotension, administer cautious fluid resuscitation (250-500 mL crystalloid boluses). If shock persists, start norepinephrine. Avoid excessive fluids that worsen RV distension.
- •Monitor for bleeding: check hemoglobin, platelet count, and renal function at baseline and periodically. Anticoagulate for at least 3 months. For unprovoked PE with high recurrence risk (age >65, residual pulmonary vascular obstruction ≥5%, antiphospholipid antibodies), extend anticoagulation indefinitely.
- •In patients with antiphospholipid syndrome, use warfarin (INR 2-3) rather than DOACs due to higher recurrence rates with DOACs.
- •Refer patients with persistent dyspnea or exercise limitation after PE for structured rehabilitation, an 8-week program improves incremental shuttle walk test by 53 m (95% CI 17.7-88.3) and quality of life.
- •Screen for chronic thromboembolic pulmonary hypertension (CTEPH) in patients with persistent dyspnea 3-6 months after PE: perform echocardiography and V/Q scan. If CTEPH is confirmed, refer to a pulmonary hypertension center for consideration of pulmonary endarterectomy.
- •What NOT to do: Do not use systemic fibrinolysis in all intermediate-risk patients, the bleeding risk (6.3% major bleeding, 2.4% stroke) outweighs the benefit. Do not place inferior vena cava filters routinely, they increase DVT risk without improving survival. Do not discharge a patient with intermediate-risk PE to home without a plan for close follow-up.
Board Review — High Yield
- •Single-question rule-out, Asking 'Is PE the most likely diagnosis?' simplifies pre-test probability and allows a D-dimer threshold of 1000 ng/mL when the answer is 'no', reducing chest imaging by 18%.
- •Apixaban vs rivaroxaban bleeding, COBRRA trial: apixaban causes 46% less clinically relevant bleeding than rivaroxaban (3.3% vs 7.1%; NNT=27), making apixaban the preferred DOAC for acute VTE.
- •CTEPH incidence, Pooled incidence of CTEPH after acute PE is 0.56% in all-comers but rises to 3.2% in survivors; unprovoked PE (OR 4.1) and recurrent VTE (OR 3.2) are strong predictors.
- •Hestia criteria for outpatient management, A randomized trial showed that patients negative for all 11 Hestia criteria can be discharged directly with a 30-day adverse event rate of only 1.1%.
- •Age-adjusted troponin cut-off, In patients ≥75 years, use hsTnT ≥45 pg/mL (not 14 pg/mL) for risk stratification; this improves the C-index to 0.77 and identifies 16.6% as higher risk.
- •Pregnancy-adapted YEARS algorithm, Using 0 criteria + D-dimer <1000 ng/mL avoids CTPA in 39% of pregnant women (65% in first trimester) with a 0.21% 3-month VTE failure rate.
- •Thrombolysis in intermediate-risk PE, PEITHO trial: tenecteplase reduces death or decompensation from 5.6% to 2.6% (NNT=34) but increases major bleeding from 1.2% to 6.3% (NNH=20) and stroke from 0.2% to 2.4%, reserved for deterioration.
- •Reduced-dose apixaban for cancer, After 6 months of full-dose anticoagulation, apixaban 2.5 mg BID is noninferior to 5 mg BID for preventing recurrent VTE (2.1% vs 2.8%) and reduces clinically relevant bleeding (12.1% vs 15.6%; NNT=28).
- •RV dilation on CT, RV/LV ratio >1.0 on CT is the strongest predictor of PE-related death (OR 7.35), outperforming clinical scores alone.
- •Post-PE rehabilitation, An 8-week exercise program improves incremental shuttle walk test by 53 m and quality of life in patients with persistent dyspnea after PE.
Deep Dive — Evidence Details
1. Definition, Classification and Nomenclature
- ▸PE classification based on hemodynamics and RV function
- ▸CTEPH is a late complication in ~4% of survivors
Pulmonary embolism (PE) is obstruction of pulmonary arteries by thrombus, usually from lower extremity DVT. Synonyms: pulmonary thromboembolism, VTE (with DVT). High-risk (massive) PE: sustained hypotension (SBP <90 mmHg ≥15 min) [11]B2b. Intermediate-risk (submassive): normotensive with RV dysfunction on echo or elevated biomarkers (troponin, NT-proBNP) [11]B2b[14]B2a. Low-risk: no RV dysfunction, normal biomarkers. CTEPH is chronic sequelae with pulmonary hypertension >25 mmHg at rest >6 months after PE [13]D5.
| Category | Key Feature | Defining Criteria | Supporting Evidence |
|---|---|---|---|
| High-risk | Hemodynamic instability | Sustained hypotension or shock | [11]B2b |
| Intermediate-high | RV dysfunction + elevated biomarkers | Both present | [11]B2b |
| Intermediate-low | Either RV dysfunction or elevated biomarkers | One present | [11]B2b |
| Low-risk | No RV dysfunction, normal biomarkers | None of the above | [11]B2b |
| CTEPH | Chronic pulmonary hypertension | PA pressure >25 mmHg >6 months after PE | [13]D5 |
Pearl: The single most critical decision in acute PE is the initial hemodynamic assessment: a patient with sustained hypotension (systolic BP <90 mmHg) is high-risk and warrants immediate reperfusion, while every normotensive patient requires systematic risk stratification using RV imaging and cardiac biomarkers to guide the intensity of management.
2. Pathophysiology and Mechanism
- ▸Acute RV overload → hemodynamic collapse
- ▸CTEPH involves fibrin resistance and chronic inflammation
Acute PE causes mechanical obstruction and neurohumoral vasoconstriction (thromboxane A₂, serotonin) [37]D5, increasing pulmonary vascular resistance and RV afterload. RV dilation, wall stress, and ischemia lead to right heart failure. Incomplete clot resolution (fibrin resistant to lysis [33]B3b) with chronic inflammation (macrophages, T cells) and smooth muscle cell modulation drives CTEPH. PAR1 inhibition may be a future target [13]D5. Nonthrombotic PE (fat, amniotic fluid, tumor) triggers severe inflammation.
Pearl: In acute PE, the degree of RV overload is the central determinant of hemodynamic instability; in chronic PE, the transition from a lytic-resistant fibrin scaffold to a macrophage-driven inflammatory milieu marks the pathobiological shift toward CTEPH, and PAR1 inhibition may offer a future pharmacologic target to interrupt this cascade [13]D5[33]B3b.
3. Epidemiology, Etiology and Risk Factors
- ▸RV dysfunction and BNP are strongest predictors of mortality
- ▸CTEPH risk higher in unprovoked PE
PE incidence in all-comers: CTEPH in 0.56% (95% CI 0.1-1.0%), rising to 3.2% in survivors [47]A1a. 30-day adverse outcomes: 7.4% in normotensive derivation cohort, 4.5% validation [44]B2b. Intermediate-risk: 10.3% with anticoagulation alone vs 4.0% with catheter-directed fibrinolysis [52]A1b. Cancer-associated PE outpatient mortality 1.74% [39]A1a.
| Risk Factor | Odds Ratio (95% CI) | Evidence Level | Source |
|---|---|---|---|
| Elevated BNP/NT-proBNP for complicated in-hospital course | OR 6.8 (4.4-10) | High | [42]A1a |
| Elevated BNP/NT-proBNP for 30-day mortality | OR 7.6 (3.4-17) | High | [42]A1a |
| RV dilation on CT for 30-day mortality | OR 2.08 (1.63-2.66) | High | [46]A1a |
| RV dilation on CT for PE-related death | OR 7.35 (3.59-15.09) | High | [46]A1a |
| Unprovoked PE for CTEPH | OR 4.1 (2.1-8.2) | Moderate | [47]A1a |
| Recurrent VTE for CTEPH | OR 3.2 (1.7-5.9) | Moderate | [47]A1a |
Pearl: The risk of PE-related death is most strongly predicted by right ventricular dysfunction (OR 7.35) and elevated BNP (OR 7.6), these biomarkers are essential for refining risk stratification beyond clinical factors alone.
4. Clinical Presentation
- ▸Dyspnea is most common symptom
- ▸Syncope suggests large central embolus
Symptoms: dyspnea (most common), pleuritic chest pain, cough, hemoptysis, syncope. Signs: tachypnea, tachycardia (HR ≥110 bpm → aOR 1.87 for adverse outcomes [58]B2b), hypotension (SBP 90-100 mmHg → aOR 2.45 [58]B2b), hypoxia (SpO₂ <90% → increased 30-day mortality in cancer [61]B2b), RV strain (elevated JVP, loud P2, tricuspid regurgitation). Red flags: SBP <90 mmHg, HR ≥110 bpm with RV strain, syncope, oxygen saturation <90%. Atypical: COPD exacerbation (24.7% PE prevalence [64]B2a), cancer patients (asymptomatic UPE 30-day mortality 3% vs 20-21% symptomatic [61]B2b).
Pearl: A normotensive patient with PE and heart rate ≥110 bpm, SBP 90-100 mmHg, or oxygen saturation <90% is at intermediate risk and warrants urgent risk stratification [58]B2b[61]B2b.
| Sign | Adjusted Odds Ratio (95% CI) | Source |
|---|---|---|
| Systolic blood pressure 90-100 mmHg | 2.45 (1.50-3.99) | Bova et al. [58]B2b |
| Heart rate ≥110 beats/min | 1.87 (1.31-2.69) | Bova et al. [58]B2b |
| Elevated cardiac troponin | 2.49 (1.71-3.69) | Bova et al. [58]B2b |
| Right ventricular dysfunction (echocardiography) | 2.28 (1.58-3.29) | Bova et al. [58]B2b |
5. Diagnosis and Workup
- ▸D-dimer 1000 ng/mL threshold for low probability
- ▸CTPA is reference standard
Step 1: Assess clinical probability (single question: "Is PE most likely?" [75]B2b). Step 2: D-dimer. If low probability, threshold 1000 ng/mL rules out PE (failure rate 0.00%) [75]B2b. If moderate probability, threshold 500 ng/mL. High probability: proceed directly to imaging. Step 3: CTPA is gold standard (3-month VTE risk after negative CTPA 0.0% [21]A1b). Alternatives: V/Q scan (planar or SPECT) when contrast contraindicated. Step 4: Point-of-care ultrasound can identify high-specificity signs (e.g., DVT + normal anterior lung profile → specificity 99% [67]B2b).
Pearl: The single question "Is PE the most likely diagnosis?" can replace complex scoring systems and safely allow a 1000 ng/mL D-dimer threshold, reducing chest imaging by nearly 20 percentage points [75]B2b.
6. Severity, Staging and Risk Stratification
- ▸sPESI=0 identifies low-risk (30-day mortality ~1%)
- ▸Bova score stage III → 29.2% complication rate
After diagnosis, stratify risk using PESI/sPESI (sPESI=0 → 30-day mortality ~1% [85]D5) and Hestia criteria. Biomarkers: elevated BNP/NT-proBNP (OR 6.8 for complicated course, OR 7.6 for 30-day mortality [42]A1a), troponin (aOR 2.49 [58]B2b), copeptin ≥24 pmol/L (5.4-fold increased risk [86]B2b). Imaging: RV dilation on CT (OR 2.08 for 30-day mortality, OR 7.35 for PE-related death [46]A1a). Bova score integrates SBP 90-100, HR ≥110, troponin, RV dysfunction → 30-day complication rates: 4.2% (stage I), 10.8% (II), 29.2% (III) [58]B2b. Low-risk patients (sPESI=0, Hestia negative) can be managed as outpatients.
Pearl: The single most important decision is distinguishing normotensive patients with RV dysfunction from those without; this separates intermediate-risk from low-risk PE and determines whether escalation to reperfusion therapy may be warranted.
| Tool | Components | Risk Categories | 30-day Outcome |
|---|---|---|---|
| sPESI | Age >80, cancer, chronic cardiopulmonary disease, HR ≥110, SBP <100, O2 sat <90% | 0 = low-risk; ≥1 = higher risk | Low-risk mortality ~1% [85]D5 |
| Hestia criteria | 11 items: hemodynamic instability, hypoxia, bleeding risk, comorbidity, etc. | Negative = low-risk | Adverse outcome 1.1% (0.2-3.2%) [40]A1b |
| Bova score | SBP 90-100 (2 pts), HR ≥110 (1 pt), elevated troponin (2 pts), RV dysfunction (2 pts) | Stage I (0-2): 4.2%; Stage II (3-4): 10.8%; Stage III (>4): 29.2% [58]B2b | PE-related death, collapse, or recurrent PE |
| PREP model | Altered mental state, shock, cancer, BNP, RV/LV ratio | Continuous score; AUC 0.84 (0.78-0.90) [83]B2b | 30-day adverse events |
| PROTECT multimarker | sPESI + troponin I + BNP + lower limb ultrasound | NPV 99.1-100% for complicated course [44]B2b | All-cause mortality, collapse, recurrent PE |
7. Acute Management and Exacerbation Rescue
- ▸Apixaban has lower bleeding risk than rivaroxaban
- ▸Fibrinolysis reserved for high-risk or deteriorating intermediate-risk
Triage: low-risk → outpatient (Hestia criteria), intermediate/high-risk → inpatient. Start anticoagulation immediately: DOACs preferred. Apixaban 10 mg BID ×7d then 5 mg BID (lower bleeding risk than rivaroxaban: RR 0.46, NNT 26 [92]A1b). Rivaroxaban 15 mg BID ×21d then 20 mg daily. For high-risk (hypotension): immediate systemic fibrinolysis (tenecteplase). For intermediate-risk with cardiorespiratory distress: consider ultrasound-facilitated catheter-directed fibrinolysis (NNT 16 [52]A1b). Supportive care: O₂ to target SpO₂ ≥90% (avoid routine O₂ in normoxemic). Hemodynamic support: cautious fluids, norepinephrine. Transition to long-term therapy after 3-6 months.
| Drug | Acute dose | Maintenance dose | Key trial | Bleeding vs comparator |
|---|---|---|---|---|
| Apixaban | 10 mg PO BID ×7d | 5 mg PO BID | Caravaggio [94]A1b | Major bleeding 3.8% vs 4.0% (HR 0.82) |
| Rivaroxaban | 15 mg PO BID ×21d | 20 mg PO daily | EINSTEIN-PE [96]A1b | Major bleeding 1.1% vs 2.2% (HR 0.49) |
| Edoxaban | Heparin lead-in ×5d | 60 mg PO daily (30 mg if CrCl 30-50 or ≤60 kg) | Hokusai-VTE [95]A1b | Clinically relevant bleeding 8.5% vs 10.3% (HR 0.81) |
Pearl: For acute PE, choose a DOAC (apixaban or rivaroxaban) for most patients; apixaban causes less bleeding (NNT=26 vs. rivaroxaban [92]A1b); reserve fibrinolysis for high-risk or selected intermediate-risk patients, and consider catheter-directed therapy for those with cardiorespiratory distress (NNT=16 [52]A1b).
| Drug | Acute dose | Maintenance dose | Renal adjustment | Key trial | Efficacy vs. comparator | Bleeding vs. comparator |
|---|---|---|---|---|---|---|
| Apixaban | 10 mg PO BID × 7 days | 5 mg PO BID | Avoid if CrCl <15 mL/min | Caravaggio [94]A1b | Noninferior to dalteparin (HR 0.63, 95% CI 0.37-1.07) | Major bleeding 3.8% vs. 4.0% (HR 0.82, 95% CI 0.40-1.69) |
| Rivaroxaban | 15 mg PO BID × 21 days | 20 mg PO daily | Avoid if CrCl <15 mL/min; 15 mg daily if CrCl 15-49 | EINSTEIN-PE [96]A1b | Noninferior to enoxaparin/VKA (HR 1.12, 95% CI 0.75-1.68) | Major bleeding 1.1% vs. 2.2% (HR 0.49, 95% CI 0.31-0.79) |
| Edoxaban | Heparin lead-in × 5 days | 60 mg PO daily; 30 mg if CrCl 30-50 or weight ≤60 kg | Avoid if CrCl <30 or >95 mL/min | Hokusai-VTE [95]A1b | Noninferior to warfarin (HR 0.89, 95% CI 0.70-1.13) | Clinically relevant bleeding 8.5% vs. 10.3% (HR 0.81, 95% CI 0.71-0.94) |
8. Long-term and Definitive Management
- ▸Extended anticoagulation for unprovoked PE with high recurrence risk
- ▸Reduced-dose apixaban effective for cancer-associated VTE after 6 months
After initial 3-6 months, risk-stratify for recurrence: age >65 (HR 4.70), PVOI ≥5% at 6 months (HR 2.06), antiphospholipid antibodies (HR 2.38) [22]A1b. For unprovoked PE with high recurrence risk, extended anticoagulation indefinitely. For cancer-associated VTE, after ≥6 months, reduced-dose apixaban 2.5 mg BID is noninferior to full-dose (5 mg BID) for recurrent VTE (2.1% vs 2.8%) and reduces clinically relevant bleeding (12.1% vs 15.6%; NNT 28) [50]A1b. DOACs preferred over VKA for non-cancer (CHEST 2016 Grade 2B) [4]A1c. For cancer, LMWH or DOAC (Grade 2C) [4]A1c. Antiphospholipid syndrome: VKA INR 2-3 (DOACs contraindicated).
Pearl: For long-term management after PE, risk-stratify using age, pulmonary vascular obstruction index, and antiphospholipid antibodies (PADIS-PE) to guide extended anticoagulation; apixaban appears to have a lower bleeding risk than rivaroxaban in the acute phase (COBRRA), and reduced-dose apixaban is a noninferior option for extended therapy in cancer-associated VTE (API-CAT).
9. Respiratory Support, Procedures & Interventional Pulmonology
- ▸Mechanical thrombectomy effective in massive PE
- ▸Pulmonary endarterectomy for CTEPH
In massive PE, mechanical thrombectomy can be life-saving, even in lung transplant recipients [118]C4. Bronchoscopic cryoextraction restores airway patency from thrombi [110]C4. Bronchial artery embolization for hemoptysis [111]D5. ECMO with concurrent procedures: hemorrhagic complications in 26% [105]B2a. IVC filters: retrieval rate 66.3% in lung transplant recipients [112]C4. Donor lungs with PE can be salvaged with backtable thromboendarterectomy [117]C4. Pulmonary endarterectomy for CTEPH: immediate postoperative PVR <590 dynes·s·cm⁻⁵ predicts better survival [104]B2b.
| Procedure | Indication | Key Evidence | Clinical Outcome |
|---|---|---|---|
| Mechanical thrombectomy | Acute massive PE in lung transplant recipients | [118]C4 | Immediate hemodynamic improvement |
| Cryoextraction | Airway obstruction from PE thrombi | [110]C4 | Partial/complete patency restoration |
| Bronchial artery embolization | Hemoptysis from PE | [111]D5 | Effective hemostasis |
| Pulmonary endarterectomy | CTEPH | [104]B2b | PVR normalization if PVR <590 dynes·s·cm⁻⁵ |
| IVC filter placement | VTE in lung transplant recipients | [112]C4 | Retrieval rate 66.3% |
Pearl: In lung transplant recipients, a high index of suspicion for PE is warranted given the 8.6% incidence and associated hypercoagulable abnormalities; mechanical thrombectomy and IVC filters can be safely employed in this population, and donor lungs with PE can be used after backtable thromboendarterectomy.
10. Complications
- ▸CTEPH occurs in 3.2% of survivors
- ▸Major bleeding risk highest in cancer-PE
Acute: RV failure (Bova score stage III complication rate 29.2% [58]B2b), bleeding (major bleeding 2.71% at 30 days in cancer-PE [39]A1a; reduced-dose apixaban 12.1% vs full-dose 15.6% [50]A1b), recurrent VTE (1.26% at 30 days [39]A1a), HIT (1.2-1.5% [119]A1a). Chronic: CTEPH (0.56% all-comers, 3.2% survivors [47]A1a), residual pulmonary vascular obstruction (28.4% [125]B2b), exercise pulmonary hypertension (40.2% of symptomatic patients [126]B2b). Prevention: risk stratification, appropriate anticoagulation, early mobilization.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Major bleeding | 2.71% at 30d (cancer-PE) [39]A1a | Risk stratification; reduced-dose apixaban | Anticoagulant reversal, transfusion |
| Recurrent VTE | 1.26% at 30d [39]A1a | Adequate anticoagulation | Reassess, consider catheter-directed therapy |
| CTEPH | 0.56% all-comers; 3.2% survivors [47]A1a | Early detection of residual obstruction | PEA, riociguat |
| RPVO | 28.4% [125]B2b | Not established | Surveillance, consider long-term anticoagulation |
| HIT | 1.2% (LMWH) vs 1.5% (UH) [119]A1a | Platelet monitoring if risk >1% [8]A1c | Argatroban, lepirudin, danaparoid |
| Exercise PH | 40.2% [126]B2b | Not established | Exercise rehab, pulmonary vasodilators |
Pearl: The 0.56% CTEPH incidence in all-comers after PE is lower than often quoted, but the 3.2% incidence in survivors highlights the need for structured follow-up in patients with persistent dyspnea, especially after unprovoked or recurrent PE [47]A1a.
11. Prognosis and Natural History
- ▸Normotensive PE mortality ~2-4% with risk stratification
- ▸Bova stage III: 29.2% complication rate
30-day mortality: low-risk ~1.9% [129]A1a, unselected normotensive ~7.4% [83]B2b, high-risk on ECMO 42.8% [49]A1a. Intermediate-risk placebo group in PEITHO: 5.6% death/decompensation at 7 days [93]A1b. Bova score stage III: 29.2% complication rate [58]B2b. Treatment effect: apixaban vs rivaroxaban lower bleeding (RR 0.46, NNT 27) [92]A1b; tenecteplase reduces decompensation (NNT 34) but increases major bleeding (NNH 20) [93]A1b; catheter-directed fibrinolysis reduces composite (RR 0.39, NNT 16) [52]A1b. Long-term: CTEPH in 3.2% survivors [47]A1a; cancer patients on extended reduced-dose apixaban mortality ~17.7% at 12 months [50]A1b.
Pearl: The 30-day mortality in normotensive PE is low (≈2-4%) with appropriate risk stratification, but intermediate-risk patients (Bova stage III) have a 29.2% complication rate, these patients may benefit from escalation of therapy beyond anticoagulation alone [58]B2b.
| Score | Components | Risk Categories | 30-Day Complication Rate |
|---|---|---|---|
| sPESI + BNP | Age >80, cancer, chronic cardiopulmonary disease, HR ≥110, SBP <100, O2 sat <90%; BNP >500 ng/L | Low vs high | NPV 99.1-100% for complicated course [44]B2b |
| Bova | SBP 90-100 mmHg, HR ≥110, elevated troponin, RVD | Stage I (0-2), II (3-4), III (5-7) | 4.2%, 10.8%, 29.2% [58]B2b |
| Hestia | 11 clinical criteria (hemodynamic instability, hypoxia, bleeding risk, etc.) | Low risk (none met) | 1.1% (95% CI 0.2-3.2%) [40]A1b |
12. Special Populations & Pregnancy
- ▸YEARS algorithm with D-dimer 1000 ng/mL in pregnancy
- ▸Age-adjusted hsTnT cut-off 45 pg/mL for ≥75 years
Pregnancy: YEARS algorithm with D-dimer threshold 1000 ng/mL (no YEARS criteria) avoids CTPA in 39% (65% in first trimester) [30]B2b. If imaging needed, V/Q preferred over CTPA [1]A1c. Cesarean section VTE risk OR 3.7 [130]A1a. Sickle cell disease: PE risk RR 7.74 [128]A1a. LMWH preferred over UFH (fewer fetal losses, RR 0.47 [143]A1a). Elderly: age-adjusted hsTnT cut-off 45 pg/mL for ≥75 years improves risk stratification (OR 4.56) [135]B2b. Cancer: perioperative LMWH reduces wound hematoma (RR 0.70) [138]A1a. Extended anticoagulation in acutely ill medical patients reduces VTE (RR 0.60) but increases major bleeding (RR 2.05) [137]A1a.
Pearl: In pregnancy, the YEARS algorithm with a D‑dimer threshold of 1000 ng/mL (when no YEARS criteria are present) safely avoids CTPA in up to two‑thirds of women in the first trimester; in patients aged ≥75 years, use a hsTnT cut‑off of 45 pg/mL rather than 14 pg/mL for risk stratification.
13. Prevention, Screening & Surveillance
- ▸Thromboprophylaxis for 10-35 days after orthopedic surgery
- ▸DOACs preferred over VKA for secondary prevention
Primary prevention: thromboprophylaxis after major orthopedic surgery (LMWH, DOACs, aspirin, IPC) for 10-35 days (Grade 1B) [6]A1c. No routine Doppler screening before discharge (Grade 1B) [6]A1c. Statins may slightly reduce VTE (OR 0.86) but not PE [149]A1a. Olanzapine increases VTE risk (OR 2.07) [156]A1a. Secondary prevention: CHEST 2016 recommends DOACs over VKA for non-cancer VTE (Grade 2B) [4]A1c. For cancer, LMWH or DOAC (Grade 2C) [4]A1c. If recurrence on DOAC, switch to LMWH (Grade 2C) [4]A1c. Subsegmental PE without proximal DVT: clinical surveillance if low risk (Grade 2C) [4]A1c. IVC filters not recommended routinely (Grade 1B) [4]A1c.
Pearl: The most impactful prevention strategy is appropriate thromboprophylaxis in hospitalized surgical and medical patients, guided by validated risk scores; the CHEST guidelines recommend against routine Doppler screening before discharge after orthopedic surgery, emphasizing that pharmacologic prophylaxis, not surveillance, is the cornerstone of prevention.
| Population | Recommended Prophylaxis | Duration | Grade | Source |
|---|---|---|---|---|
| Major orthopedic surgery | LMWH, fondaparinux, DOACs, LDUH, VKA, aspirin, or IPCD | Minimum 10-14 days, extend to 35 days | 1B (pharmacologic), 1C (IPCD) | CHEST 2012 [6]A1c |
| Hemodynamically unstable pelvic fractures | Early chemoprophylaxis (initiate hospital day 1) | Ongoing during hospitalization | , | Observational [159]B2b |
| Degenerative spine surgery | Maintain thromboembolic vigilance for up to 4 months | Extended beyond typical perioperative window | , | Observational [157]B2b |
| General medical patients with no prior VTE | Statins not recommended for primary PE prevention | , | Low-certainty evidence | Cochrane 2024 [149]A1a |
| Patients on olanzapine | Enhanced clinical surveillance | , | , | Meta-analysis [156]A1a |
References
- [1]
Leung AN, Bull TM, Jaeschke R et al.. “An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy.” American journal of respiratory and critical care medicine (2011). PMID: 22086989 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, History and Evolution of Treatment, 11. Prognosis and Natural History, 12. Special Populations & Pregnancy - [2]
Lahm T, Douglas IS, Archer SL et al.. “Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement.” American journal of respiratory and critical care medicine (2018). PMID: 30109950 ↗
L5GUIDELINECited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management, 10. Complications - [3]
Stevens SM, Woller SC, Kreuziger LB et al.. “Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.” Chest (2021). PMID: 34352278 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 11. Prognosis and Natural History - [4]
Kearon C, Akl EA, Ornelas J et al.. “Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.” Chest (2016). PMID: 26867832 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 8. Long-term and Definitive Management, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance - [5]
Kearon C, Akl EA, Comerota AJ et al.. “Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest (2012). PMID: 22315268 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, 3. Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment - [6]
Falck-Ytter Y, Francis CW, Johanson NA et al.. “Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest (2012). PMID: 22315265 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance - [7]
Stevens SM, Woller SC, Baumann Kreuziger L et al.. “Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report.” Chest (2021). PMID: 34352279 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 11. Prognosis and Natural History - [8]
Linkins LA, Dans AL, Moores LK et al.. “Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.” Chest (2012). PMID: 22315270 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature, History and Evolution of Treatment, 10. Complications - [9]
Moores LK, Tritschler T, Brosnahan S et al.. “Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report.” Chest (2020). PMID: 32502594 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature - [10]
Eikelboom JW, Karthikeyan G, Fagel N et al.. “American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients?” Chest (2009). PMID: 19201714 ↗
L5GUIDELINECited in: 1. Definition, Classification and Nomenclature - [11]
Hellenkamp K, Pruszczyk P, Jiménez D et al.. “Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study.” The European respiratory journal (2018). PMID: 29599188 ↗
L2PROSPECTIVE_COHORTCited in: 1. Definition, Classification and Nomenclature - [12]
Piroth L, Cottenet J, Mariet AS et al.. “Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study.” The Lancet. Respiratory medicine (2020). PMID: 33341155 ↗
L3RETROSPECTIVE_COHORTCited in: 1. Definition, Classification and Nomenclature, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications - [13]
Viswanathan G, Kirshner HF, Nazo N et al.. “Single-Cell Analysis Reveals Distinct Immune and Smooth Muscle Cell Populations that Contribute to Chronic Thromboembolic Pulmonary Hypertension.” American journal of respiratory and critical care medicine (2023). PMID: 36803741 ↗
L5OTHERCited in: 1. Definition, Classification and Nomenclature, 2. Pathophysiology and Mechanism - [14]
Cimini LA, Candeloro M, Pływaczewska M et al.. “Prognostic role of different findings at echocardiography in acute pulmonary embolism: a critical review and meta-analysis.” ERJ open research (2023). PMID: 37009027 ↗
L2SR_COHORTCited in: 1. Definition, Classification and Nomenclature - [15]
O'Connor D, Johnston RV, Brignardello-Petersen R et al.. “Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears).” The Cochrane database of systematic reviews (2022). PMID: 35238404 ↗
L1SR_MA_RCTCited in: 1. Definition, Classification and Nomenclature - [16]
Lloyd TD, Geneen LJ, Bernhardt K et al.. “Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery.” The Cochrane database of systematic reviews (2023). PMID: 37681564 ↗
L1SR_MA_RCTCited in: 1. Definition, Classification and Nomenclature, 12. Special Populations & Pregnancy - [17]
Junqueira DR, Zorzela LM, Perini E. “Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.” The Cochrane database of systematic reviews (2017). PMID: 28431186 ↗
L1SR_MA_RCTCited in: 1. Definition, Classification and Nomenclature - [18]
Kim TY, Ahn GJ, Cha KC et al.. “2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 5. Cardiac arrest in special circumstances.” Clinical and experimental emergency medicine (2026). PMID: 42297408 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature - [19]
Dorfman SR, Chan SS, Amanullah S et al.. “ACR Appropriateness Criteria® Chest Pain-Child.” Journal of the American College of Radiology : JACR (2026). PMID: 41729147 ↗
L1GUIDELINECited in: 1. Definition, Classification and Nomenclature - [20]
Huie TJ, Olson AL, Cosgrove GP et al.. “A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes.” Respirology (Carlton, Vic.) (2010). PMID: 20546190 ↗
L4COHORTCited in: 1. Definition, Classification and Nomenclature - [21]
Le Pennec R, Le Roux PY, Robin P et al.. “Comparison of Three Diagnostic Strategies for Suspicion of Pulmonary Embolism: Planar Ventilation-Perfusion Scan (V/Q), Computed Tomography Pulmonary Angiography (CTPA), and Single Photon Emission Computed Tomography Ventilation-Perfusion Scan (SPECT V/Q): a multicenter, non-inferiority randomised controlled trial.” The European respiratory journal (2026). PMID: 41927066 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), History and Evolution of Treatment - [22]
Tromeur C, Sanchez O, Presles E et al.. “Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial.” The European respiratory journal (2018). PMID: 29301920 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [23]
Lee LA, Bailes Z, Barnes N et al.. “Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.” The Lancet. Respiratory medicine (2020). PMID: 32918892 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [24]
. “Effects of intraoperative higher versus lower positive end-expiratory pressure during one-lung ventilation for thoracic surgery on postoperative pulmonary complications (PROTHOR): a multicentre, international, randomised, controlled, phase 3 trial.” The Lancet. Respiratory medicine (2025). PMID: 41240959 ↗
L1RCTCited in: 2. Pathophysiology and Mechanism, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 10. Complications, 11. Prognosis and Natural History - [25]
Harris B, Bailey D, Miles S et al.. “Objective analysis of tomographic ventilation-perfusion scintigraphy in pulmonary embolism.” American journal of respiratory and critical care medicine (2007). PMID: 17363770 ↗
L3PROSPECTIVE_COHORTCited in: 2. Pathophysiology and Mechanism - [26]
Scagliotti GV, Gaafar R, Nowak AK et al.. “Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.” The Lancet. Respiratory medicine (2019). PMID: 31103412 ↗
L1RCT_PHASE2Cited in: 2. Pathophysiology and Mechanism - [27]
Hemnes AR, Newman AL, Rosenbaum B et al.. “Bedside end-tidal CO2 tension as a screening tool to exclude pulmonary embolism.” The European respiratory journal (2009). PMID: 19717480 ↗
L2NON_RANDOMIZED_TRIALCited in: 2. Pathophysiology and Mechanism - [28]
Le Duc-Pennec A, Le Roux PY, Cornily JC et al.. “Diagnostic accuracy of single-photon emission tomography ventilation/perfusion lung scan in the diagnosis of pulmonary embolism.” Chest (2011). PMID: 21852295 ↗
L2PROSPECTIVE_COHORTCited in: 2. Pathophysiology and Mechanism - [29]
Salaun PY, Couturaud F, Le Duc-Pennec A et al.. “Noninvasive diagnosis of pulmonary embolism.” Chest (2010). PMID: 20724733 ↗
L2NON_RANDOMIZED_TRIALCited in: 2. Pathophysiology and Mechanism - [30]
van der Pol LM, Tromeur C, Bistervels IM et al.. “Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism.” The New England journal of medicine (2019). PMID: 30893534 ↗
L2NON_RANDOMIZED_TRIALCited in: 2. Pathophysiology and Mechanism, 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 12. Special Populations & Pregnancy - [31]
Fernandes TM, Alotaibi M, Strozza DM et al.. “Dyspnea Postpulmonary Embolism From Physiological Dead Space Proportion and Stroke Volume Defects During Exercise.” Chest (2019). PMID: 31759962 ↗
L3COHORTCited in: 2. Pathophysiology and Mechanism - [32]
Miles S, Rogers KM, Thomas P et al.. “A comparison of single-photon emission CT lung scintigraphy and CT pulmonary angiography for the diagnosis of pulmonary embolism.” Chest (2009). PMID: 19525358 ↗
L2COHORTCited in: 2. Pathophysiology and Mechanism - [33]
Morris TA, Marsh JJ, Chiles PG et al.. “Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.” American journal of respiratory and critical care medicine (2006). PMID: 16514114 ↗
L3OTHERCited in: 2. Pathophysiology and Mechanism - [34]
Delcroix M, Torbicki A, Gopalan D et al.. “ERS statement on chronic thromboembolic pulmonary hypertension.” The European respiratory journal (2021). PMID: 33334946 ↗
L1NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism - [35]
Jorens PG, Van Marck E, Snoeckx A et al.. “Nonthrombotic pulmonary embolism.” The European respiratory journal (2009). PMID: 19648522 ↗
L5NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism - [36]
Kim NH, Delcroix M, Jais X et al.. “Chronic thromboembolic pulmonary hypertension.” The European respiratory journal (2019). PMID: 30545969 ↗
L5NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism - [37]
Agnelli G, Becattini C. “Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach.” The European respiratory journal (2015). PMID: 25700388 ↗
L5NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism - [38]
Mercier O, Fadel E. “Chronic thromboembolic pulmonary hypertension: animal models.” The European respiratory journal (2013). PMID: 23314897 ↗
L5NARRATIVE_REVIEWCited in: 2. Pathophysiology and Mechanism - [39]
Delluc A, Pradier M, Siegal DM et al.. “Outpatient management of cancer-associated pulmonary embolism: a systematic review and meta-analysis.” The European respiratory journal (2025). PMID: 39603673 ↗
L1SR_MA_RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [40]
den Exter PL, Zondag W, Klok FA et al.. “Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial.” American journal of respiratory and critical care medicine (2016). PMID: 27030891 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [41]
Fernando SM, Tran A, Cheng W et al.. “VTE Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis.” Chest (2021). PMID: 34419428 ↗
L1SR_MA_RCTCited in: 3. Epidemiology, Etiology and Risk Factors - [42]
Klok FA, Mos IC, Huisman MV. “Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis.” American journal of respiratory and critical care medicine (2008). PMID: 18556626 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [43]
Lankeit M, Kempf T, Dellas C et al.. “Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism.” American journal of respiratory and critical care medicine (2008). PMID: 18263797 ↗
L2PROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 8. Long-term and Definitive Management, 10. Complications - [44]
Jiménez D, Kopecna D, Tapson V et al.. “Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism.” American journal of respiratory and critical care medicine (2014). PMID: 24471575 ↗
L2PROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [45]
Walsh SLF, Mackintosh JA, Calandriello L et al.. “Deep Learning-based Outcome Prediction in Progressive Fibrotic Lung Disease Using High-Resolution Computed Tomography.” American journal of respiratory and critical care medicine (2022). PMID: 35696341 ↗
L3PROSPECTIVE_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [46]
Becattini C, Agnelli G, Germini F et al.. “Computed tomography to assess risk of death in acute pulmonary embolism: a meta-analysis.” The European respiratory journal (2014). PMID: 24603813 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [47]
Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A et al.. “Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature.” The European respiratory journal (2017). PMID: 28232411 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored), 10. Complications - [48]
Squizzato A, Galli M, Dentali F et al.. “Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review.” The European respiratory journal (2009). PMID: 19407049 ↗
L2SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [49]
Chopard R, Nielsen P, Ius F et al.. “Optimal reperfusion strategy in acute high-risk pulmonary embolism requiring extracorporeal membrane oxygenation support: a systematic review and meta-analysis.” The European respiratory journal (2022). PMID: 35487534 ↗
L1SR_COHORTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [50]
Mahé I, Carrier M, Mayeur D et al.. “Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism.” The New England journal of medicine (2025). PMID: 40162636 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 10. Complications, 11. Prognosis and Natural History - [51]
Lincoff AM, Bhasin S, Flevaris P et al.. “Cardiovascular Safety of Testosterone-Replacement Therapy.” The New England journal of medicine (2023). PMID: 37326322 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [52]
Rosenfield K, Klok FA, Piazza G et al.. “Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism.” The New England journal of medicine (2026). PMID: 41910345 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 7. Acute Management and Exacerbation Rescue, 11. Prognosis and Natural History - [53]
O'Toole RV, Stein DM, O'Hara NN et al.. “Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.” The New England journal of medicine (2023). PMID: 36652352 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 10. Complications, 11. Prognosis and Natural History - [54]
Khorana AA, Soff GA, Kakkar AK et al.. “Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.” The New England journal of medicine (2019). PMID: 30786186 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors, 6. Severity, Staging and Risk Stratification - [55]
Samama CM, Laporte S, Rosencher N et al.. “Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.” The New England journal of medicine (2020). PMID: 32223113 ↗
L1RCTCited in: 3. Epidemiology, Etiology and Risk Factors - [56]
Eikelboom JW, Jolly SS, Belley-Cote EP et al.. “Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.” The Lancet. Respiratory medicine (2022). PMID: 36228641 ↗
L1RCTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History, 13. Prevention, Screening & Surveillance - [57]
Jervan Ø, Haukeland-Parker S, Gleditsch J et al.. “The Effects of Exercise Training in Patients With Persistent Dyspnea Following Pulmonary Embolism: A Randomized Controlled Trial.” Chest (2023). PMID: 37149257 ↗
L1RCTCited in: 4. Clinical Presentation, 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [58]
Bova C, Sanchez O, Prandoni P et al.. “Identification of intermediate-risk patients with acute symptomatic pulmonary embolism.” The European respiratory journal (2014). PMID: 24696111 ↗
L2SR_COHORTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification, 10. Complications, 11. Prognosis and Natural History - [59]
Decousus H, Prandoni P, Mismetti P et al.. “Fondaparinux for the treatment of superficial-vein thrombosis in the legs.” The New England journal of medicine (2010). PMID: 20860504 ↗
L1RCTCited in: 4. Clinical Presentation - [60]
Farmakis IT, Valerio L, Barco S et al.. “Cardiopulmonary exercise testing during follow-up after acute pulmonary embolism.” The European respiratory journal (2023). PMID: 36958742 ↗
L2PROSPECTIVE_COHORTCited in: 4. Clinical Presentation, 6. Severity, Staging and Risk Stratification - [61]
Font C, Carmona-Bayonas A, Beato C et al.. “Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study.” The European respiratory journal (2017). PMID: 28052954 ↗
L2PROSPECTIVE_COHORTCited in: 4. Clinical Presentation - [62]
Kline JA, Hogg MM, Courtney DM et al.. “D-dimer and exhaled CO2/O2 to detect segmental pulmonary embolism in moderate-risk patients.” American journal of respiratory and critical care medicine (2010). PMID: 20448094 ↗
L2NON_RANDOMIZED_TRIALCited in: 4. Clinical Presentation - [63]
Henzler T, Roeger S, Meyer M et al.. “Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction.” The European respiratory journal (2011). PMID: 21965223 ↗
L2NON_RANDOMIZED_TRIALCited in: 4. Clinical Presentation - [64]
Rizkallah J, Man SFP, Sin DD. “Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis.” Chest (2008). PMID: 18812453 ↗
L2SR_COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [65]
Arzt M, Luigart R, Schum C et al.. “Sleep-disordered breathing in deep vein thrombosis and acute pulmonary embolism.” The European respiratory journal (2012). PMID: 22362853 ↗
L3CASE_CONTROLCited in: 4. Clinical Presentation - [66]
Falster C, Jacobsen N, Coman KE et al.. “Diagnostic accuracy of focused deep venous, lung, cardiac and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis.” Thorax (2021). PMID: 34497138 ↗
L2SR_COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [67]
Lichtenstein DA, Mezière GA. “Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol.” Chest (2008). PMID: 18403664 ↗
L2COHORTCited in: 4. Clinical Presentation, 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [68]
Ellison AM, Kuppermann N, Shihabuddin BS et al.. “PERC-Peds rule for bedside exclusion of pulmonary embolism without radiation in children in the USA (BEEPER): a multicentre, prospective, observational, diagnostic accuracy study.” The Lancet. Respiratory medicine (2026). PMID: 42398511 ↗
L2CASE_SERIESCited in: 4. Clinical Presentation - [69]
Celli BR, Fabbri LM, Aaron SD et al.. “Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice.” American journal of respiratory and critical care medicine (2023). PMID: 36701677 ↗
L5NARRATIVE_REVIEWCited in: 4. Clinical Presentation - [70]
Rali PM, Criner GJ. “Submassive Pulmonary Embolism.” American journal of respiratory and critical care medicine (2018). PMID: 29672125 ↗
L5NARRATIVE_REVIEWCited in: 4. Clinical Presentation - [71]
Jiménez D, Aujesky D, Díaz G et al.. “Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism.” American journal of respiratory and critical care medicine (2010). PMID: 20110556 ↗
L2PROSPECTIVE_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [72]
Jiménez D, Bikdeli B, Barrios D et al.. “Management appropriateness and outcomes of patients with acute pulmonary embolism.” The European respiratory journal (2018). PMID: 29724918 ↗
L2PROSPECTIVE_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [73]
Nijkeuter M, Hovens MM, Davidson BL et al.. “Resolution of thromboemboli in patients with acute pulmonary embolism: a systematic review.” Chest (2006). PMID: 16424432 ↗
L2SR_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [74]
Aleva FE, Voets LWLM, Simons SO et al.. “Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD: A Systematic Review and Meta-analysis.” Chest (2016). PMID: 27522956 ↗
L2SR_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [75]
Roussel M, Bannelier H, Lebal S et al.. “D-Dimer thresholds for diagnosis of pulmonary embolism based on a single question: is it the most likely diagnosis? A prospective, multicentre, open-label, single-arm interventional study.” The Lancet. Respiratory medicine (2025). PMID: 41135553 ↗
L2NON_RANDOMIZED_TRIALCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [76]
Zhai Z, Wang D, Lei J et al.. “Trends in risk stratification, in-hospital management and mortality of patients with acute pulmonary embolism: an analysis from the China pUlmonary thromboembolism REgistry Study (CURES).” The European respiratory journal (2021). PMID: 33986031 ↗
L3COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [77]
Zöller B, Pirouzifard M, Memon AA et al.. “Risk of pulmonary embolism and deep venous thrombosis in patients with asthma: a nationwide case-control study from Sweden.” The European respiratory journal (2017). PMID: 28202551 ↗
L3CASE_CONTROLCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [78]
Lega JC, Lacasse Y, Lakhal L et al.. “Natriuretic peptides and troponins in pulmonary embolism: a meta-analysis.” Thorax (2009). PMID: 19525265 ↗
L1SR_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [79]
Wolf S, Valerio L, Kucher N et al.. “Acute pulmonary embolism in children and adolescents in the USA (2016 and 2019): a nationwide retrospective cohort study.” The Lancet. Respiratory medicine (2025). PMID: 39919780 ↗
L3RETROSPECTIVE_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [80]
Vanni S, Jiménez D, Nazerian P et al.. “Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate.” Thorax (2015). PMID: 25661114 ↗
L2PROSPECTIVE_COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [81]
Liao H, Na MJ, Dikensoy O et al.. “Diagnostic value of pleural fluid N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases.” Respirology (Carlton, Vic.) (2008). PMID: 18197911 ↗
L3RCTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [82]
Kearon C, de Wit K, Parpia S et al.. “Diagnosis of Pulmonary Embolism with d-Dimer Adjusted to Clinical Probability.” The New England journal of medicine (2019). PMID: 31774957 ↗
L2COHORTCited in: 5. Diagnosis and Workup (Pulmonary Function, Bronchoscopy and Imaging Anchored) - [83]
Sanchez O, Trinquart L, Caille V et al.. “Prognostic factors for pulmonary embolism: the prep study, a prospective multicenter cohort study.” American journal of respiratory and critical care medicine (2009). PMID: 19910608 ↗
L2PROSPECTIVE_COHORTCited in: 6. Severity, Staging and Risk Stratification, 11. Prognosis and Natural History - [84]
Ho KM, Rao S, Honeybul S et al.. “A Multicenter Trial of Vena Cava Filters in Severely Injured Patients.” The New England journal of medicine (2019). PMID: 31259488 ↗
L1RCTCited in: 6. Severity, Staging and Risk Stratification - [85]
Lankeit M, Konstantinides S. “Is it time for home treatment of pulmonary embolism?” The European respiratory journal (2012). PMID: 22496322 ↗
L5PROSPECTIVE_COHORTCited in: 6. Severity, Staging and Risk Stratification - [86]
Hellenkamp K, Schwung J, Rossmann H et al.. “Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin.” The European respiratory journal (2015). PMID: 26493800 ↗
L2PROSPECTIVE_COHORTCited in: 6. Severity, Staging and Risk Stratification - [87]
Mulder FI, Di Nisio M, Ay C et al.. “Clinical implications of incidental venous thromboembolism in cancer patients.” The European respiratory journal (2020). PMID: 31727694 ↗
L2RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [88]
Jiménez D, Rodríguez C, León F et al.. “Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism.” The European respiratory journal (2022). PMID: 34385269 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [89]
Ison MG, Papi A, Athan E et al.. “Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.” The Lancet. Respiratory medicine (2025). PMID: 40245915 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 13. Prevention, Screening & Surveillance - [90]
Barrios D, Durán D, Rodríguez C et al.. “Oxygen Therapy in Patients With Intermediate-Risk Acute Pulmonary Embolism: A Randomized Trial.” Chest (2023). PMID: 37717936 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment - [91]
Planquette B, Bertoletti L, Charles-Nelson A et al.. “Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.” Chest (2021). PMID: 34627853 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management - [92]
Castellucci LA, Chen VM, Kovacs MJ et al.. “Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.” The New England journal of medicine (2026). PMID: 41812192 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, History and Evolution of Treatment, 11. Prognosis and Natural History - [93]
Meyer G, Vicaut E, Danays T et al.. “Fibrinolysis for patients with intermediate-risk pulmonary embolism.” The New England journal of medicine (2014). PMID: 24716681 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue, 8. Long-term and Definitive Management, 11. Prognosis and Natural History - [94]
Agnelli G, Becattini C, Meyer G et al.. “Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.” The New England journal of medicine (2020). PMID: 32223112 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue - [95]
Büller HR, Décousus H, Grosso MA et al.. “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.” The New England journal of medicine (2013). PMID: 23991658 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue - [96]
Büller HR, Prins MH, Lensin AW et al.. “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.” The New England journal of medicine (2012). PMID: 22449293 ↗
L1RCTCited in: 7. Acute Management and Exacerbation Rescue - [97]
Rosovsky RP, Grodzin C, Channick R et al.. “Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT Consortium.” Chest (2020). PMID: 32861692 ↗
L1GUIDELINECited in: 8. Long-term and Definitive Management - [98]
Girard P, Decousus M, Laporte S et al.. “Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy.” American journal of respiratory and critical care medicine (2001). PMID: 11587992 ↗
L2RCTCited in: History and Evolution of Treatment - [99]
Izbicki G, Bairey O, Shitrit D et al.. “Increased thromboembolic events after lung transplantation.” Chest (2006). PMID: 16478860 ↗
L3COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [100]
Chieng H, Saha B, Foulke L et al.. “A 24-Year-Old Man With Dyspnea and a Broken Left Femur.” Chest (2022). PMID: 35396056 ↗
L4CASE_SERIESCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [101]
Egan T, Blackwell J, Birchard K et al.. “Assessment of Lungs for Transplant Recovered from Uncontrolled Donation after Circulatory Determination of Death Donors.” Annals of the American Thoracic Society (2017). PMID: 28945476 ↗
L2NON_RANDOMIZED_TRIALCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [102]
Lankeit M, Dellas C, Panzenböck A et al.. “Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension.” The European respiratory journal (2008). PMID: 18256058 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [103]
Bax S, Jacob J, Ahmed R et al.. “Right Ventricular to Left Ventricular Ratio at CT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease.” Chest (2019). PMID: 31351047 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [104]
Skoro-Sajer N, Marta G, Gerges C et al.. “Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy.” Thorax (2013). PMID: 24052543 ↗
L2OTHERCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [105]
Neri G, Mazza G, Mastrangelo H et al.. “Safety of Invasive Procedures During Adult Extracorporeal Membrane Oxygenation: A Systematic Review.” Journal of clinical medicine (2026). PMID: 42355959 ↗
L2SR_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [106]
Liang G, Peng H, Li Y. “Clinical efficacy and safety of robotic-assisted thoracic surgery after neoadjuvant therapy in non-small cell lung cancer: a systematic review and meta-analysis.” Updates in surgery (2026). PMID: 41729427 ↗
L2SR_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [107]
Hosokawa K, Masaki K, Hirose M et al.. “Long-term real-world effectiveness and safety of edoxaban in chronic thromboembolic pulmonary hypertension: a nationwide registry study.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42315026 ↗
L2PROSPECTIVE_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [108]
Rangwala HS, Rangwala BS, Alotaibi M et al.. “Clinical Outcomes with High- versus Low-Dose Tranexamic Acid Infusion in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.” The Thoracic and cardiovascular surgeon (2025). PMID: 39842460 ↗
L1SR_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [109]
Madeka I, Noueihed K, Woodroof J et al.. “Lymph Node Dissection and Postoperative Complications After Lung Cancer Resection.” JAMA network open (2026). PMID: 42223938 ↗
L3RETROSPECTIVE_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [110]
Truitt BA, Kasi AS, Kamat PP et al.. “Cryoextraction via flexible bronchoscopy in children with tracheobronchial obstruction.” Pediatric pulmonology (2023). PMID: 37350368 ↗
L4COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [111]
. “[Expert consensus on operational procedures for bronchial artery embolization in the treatment of hemoptysis].” Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (2025). PMID: 40300866 ↗
L5GUIDELINECited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [112]
Naser-Tavakolian K, Sajan A, Krishnasamy VP et al.. “Outcomes of inferior vena cava filtration in lung transplant recipients.” Frontiers in radiology (2026). PMID: 41947864 ↗
L4RETROSPECTIVE_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [113]
Kim NT, Miyashita Y, Kaihou T et al.. “Risk factors and perioperative complications associated with deep venous thrombosis and pulmonary embolism after lung transplantation.” Journal of thoracic disease (2025). PMID: 41376962 ↗
L3RETROSPECTIVE_COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [114]
Kamar A, Miyashita Y, Kaiho T et al.. “Risk factors and clinical outcomes of serum Aspergillus galactomannan antigen (AGA) positivity in lung transplantation.” Journal of thoracic disease (2025). PMID: 41229833 ↗
L3COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [115]
Liu J, Bao B, Zhang T et al.. “Comparative analysis of the clinical characteristics of severe Mycoplasma pneumoniae pneumonia and severe bacterial pneumonia in children.” BMC pediatrics (2025). PMID: 40448048 ↗
L3COHORTCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [116]
Li H, Li SD, Jiang QC et al.. “Case Report: Early diaphragmatic plication for combined phrenic and recurrent laryngeal nerve injury after VATS thymectomy.” Frontiers in medicine (2026). PMID: 42454123 ↗
L4CASE_SERIESCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [117]
Williams AM, Kathawate RG, Khosravi R et al.. “Utilizing lung donors with recent massive pulmonary emboli and chronic thromboembolic disease for transplantation.” American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2024). PMID: 39447751 ↗
L4CASE_SERIESCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [118]
Altun I, Zhao Y, Basnet S et al.. “The Role of Mechanical Thrombectomy for Acute Massive Pulmonary Embolism in a Patient With Unilateral Lung Transplant and Atrial Septal Defect.” Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists (2023). PMID: 37776207 ↗
L4CASE_SERIESCited in: 9. Respiratory Support, Procedures & Interventional Pulmonology (Specialty-Distinctive) - [119]
Morris TA, Castrejon S, Devendra G et al.. “No difference in risk for thrombocytopenia during treatment of pulmonary embolism and deep venous thrombosis with either low-molecular-weight heparin or unfractionated heparin: a metaanalysis.” Chest (2007). PMID: 17646239 ↗
L1SR_MA_RCTCited in: 10. Complications - [120]
Shivakumar S, Matino D, Zukor D et al.. “Rivaroxaban Then Aspirin vs. Aspirin Alone after Total Hip or Knee Arthroplasty.” The New England journal of medicine (2026). PMID: 42437501 ↗
L1RCTCited in: 10. Complications - [121]
Anderson DR, Dunbar M, Murnaghan J et al.. “Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.” The New England journal of medicine (2018). PMID: 29466159 ↗
L1RCTCited in: 10. Complications - [122]
Myles PS, Smith JA, Forbes A et al.. “Stopping vs. Continuing Aspirin before Coronary Artery Surgery.” The New England journal of medicine (2016). PMID: 26933848 ↗
L1RCTCited in: 10. Complications, 12. Special Populations & Pregnancy - [123]
Myles PS, Smith JA, Forbes A et al.. “Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.” The New England journal of medicine (2016). PMID: 27774838 ↗
L1RCTCited in: 10. Complications, 12. Special Populations & Pregnancy - [124]
Goldhaber SZ, Leizorovicz A, Kakkar AK et al.. “Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.” The New England journal of medicine (2011). PMID: 22077144 ↗
L1RCTCited in: 10. Complications - [125]
Planquette B, Sanchez O, Marsh JJ et al.. “Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment.” The European respiratory journal (2018). PMID: 30337447 ↗
L2PROSPECTIVE_COHORTCited in: 10. Complications - [126]
Martín de Miguel I, Jiménez López-Guarch C, Segura de La Cal T et al.. “Chronic Thromboembolic Pulmonary Disease With Exercise Pulmonary Hypertension: A Noninvasive Model to Predict Exercise Hemodynamics.” Chest (2025). PMID: 41238055 ↗
L2PROSPECTIVE_COHORTCited in: 10. Complications - [127]
George PM, Barratt SL, Condliffe R et al.. “Respiratory follow-up of patients with COVID-19 pneumonia.” Thorax (2020). PMID: 32839287 ↗
L5SR_COHORTCited in: 10. Complications - [128]
Inparaj S, Buckingham M, Oakley L et al.. “Pulmonary complications for women with sickle cell disease in pregnancy: systematic review and meta-analysis.” Thorax (2020). PMID: 32345690 ↗
L1SR_COHORTCited in: 10. Complications, 12. Special Populations & Pregnancy - [129]
Zondag W, Kooiman J, Klok FA et al.. “Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis.” The European respiratory journal (2012). PMID: 23100493 ↗
L1SR_COHORTCited in: 11. Prognosis and Natural History - [130]
Blondon M, Casini A, Hoppe KK et al.. “Risks of Venous Thromboembolism After Cesarean Sections: A Meta-Analysis.” Chest (2016). PMID: 27262227 ↗
L1SR_COHORTCited in: 12. Special Populations & Pregnancy - [131]
Davies CW, Wimperis J, Green ES et al.. “Early discharge of patients with pulmonary embolism: a two-phase observational study.” The European respiratory journal (2007). PMID: 17567672 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy - [132]
Tafelmeier M, Luft L, Zistler E et al.. “Central Sleep Apnea Predicts Pulmonary Complications After Cardiac Surgery.” Chest (2020). PMID: 32798522 ↗
L2COHORTCited in: 12. Special Populations & Pregnancy - [133]
Sheen JJ, Haramati LB, Natenzon A et al.. “Performance of Low-Dose Perfusion Scintigraphy and CT Pulmonary Angiography for Pulmonary Embolism in Pregnancy.” Chest (2017). PMID: 28823756 ↗
L2RETROSPECTIVE_COHORTCited in: 12. Special Populations & Pregnancy - [134]
Wiesen MH, Blaich C, Müller C et al.. “The Direct Factor Xa Inhibitor Rivaroxaban Passes Into Human Breast Milk.” Chest (2016). PMID: 27396794 ↗
L4CASE_SERIESCited in: 12. Special Populations & Pregnancy - [135]
Kaeberich A, Seeber V, Jiménez D et al.. “Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism.” The European respiratory journal (2015). PMID: 25614162 ↗
L2OTHERCited in: 12. Special Populations & Pregnancy - [136]
Middleton P, Shepherd E, Gomersall JC. “Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period.” The Cochrane database of systematic reviews (2021). PMID: 33779986 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy - [137]
Kolkailah AA, Abdelghaffar B, Elshafeey F et al.. “Standard- versus extended-duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients.” The Cochrane database of systematic reviews (2024). PMID: 39629741 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy - [138]
Matar CF, Kahale LA, Hakoum MB et al.. “Anticoagulation for perioperative thromboprophylaxis in people with cancer.” The Cochrane database of systematic reviews (2018). PMID: 29993117 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy - [139]
Perel P, Ker K, Morales Uribe CH et al.. “Tranexamic acid for reducing mortality in emergency and urgent surgery.” The Cochrane database of systematic reviews (2013). PMID: 23440847 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy - [140]
Akl EA, Kahale L, Sperati F et al.. “Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.” The Cochrane database of systematic reviews (2014). PMID: 24966161 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy - [141]
Akl EA, Labedi N, Terrenato I et al.. “Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.” The Cochrane database of systematic reviews (2011). PMID: 22071865 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy - [142]
Okusanya BO, Oladapo OT. “Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy.” The Cochrane database of systematic reviews (2016). PMID: 28005272 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy - [143]
Bain E, Wilson A, Tooher R et al.. “Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.” The Cochrane database of systematic reviews (2014). PMID: 24519568 ↗
L1SR_MA_RCTCited in: 12. Special Populations & Pregnancy - [144]
Wiener RS, Ouellette DR, Diamond E et al.. “An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine.” Chest (2014). PMID: 24889436 ↗
L5GUIDELINECited in: 13. Prevention, Screening & Surveillance - [145]
Reddy SA, Newman J, Leavy OC et al.. “Chronic thromboembolic pulmonary hypertension is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies.” The European respiratory journal (2024). PMID: 39060016 ↗
L2COHORTCited in: 13. Prevention, Screening & Surveillance - [146]
Hajduk B, Tomkowski WZ, Malek G et al.. “Vena cava filter occlusion and venous thromboembolism risk in persistently anticoagulated patients: a prospective, observational cohort study.” Chest (2009). PMID: 19880907 ↗
L2PROSPECTIVE_COHORTCited in: 13. Prevention, Screening & Surveillance - [147]
Ghincea A, Ryu C, Herzog EL. “An Acute Exacerbation of Idiopathic Pulmonary Fibrosis After BNT162b2 mRNA COVID-19 Vaccination: A Case Report.” Chest (2022). PMID: 35131075 ↗
L4CASE_SERIESCited in: 13. Prevention, Screening & Surveillance - [148]
Li L, Sun T, Zhang P et al.. “Statins for primary prevention of venous thromboembolism.” The Cochrane database of systematic reviews (2011). PMID: 22161421 ↗
L1SR_MA_RCTCited in: 13. Prevention, Screening & Surveillance - [149]
Wang Z, Zhang P, Tian J et al.. “Statins for the primary prevention of venous thromboembolism.” The Cochrane database of systematic reviews (2024). PMID: 39498835 ↗
L1SR_MA_RCTCited in: 13. Prevention, Screening & Surveillance - [150]
Li L, Zhang P, Tian JH et al.. “Statins for primary prevention of venous thromboembolism.” The Cochrane database of systematic reviews (2014). PMID: 25518837 ↗
L1SR_MA_RCTCited in: 13. Prevention, Screening & Surveillance - [151]
Greinacher A, Thiele T, Warkentin TE et al.. “Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination.” The New England journal of medicine (2021). PMID: 33835769 ↗
L4CASE_SERIESCited in: 13. Prevention, Screening & Surveillance - [152]
Carlbom DJ, Davidson BL. “Pulmonary embolism in the critically ill.” Chest (2007). PMID: 17625093 ↗
L5NARRATIVE_REVIEWCited in: 13. Prevention, Screening & Surveillance - [153]
George MG, Schieb LJ, Ayala C et al.. “Pulmonary hypertension surveillance: United States, 2001 to 2010.” Chest (2014). PMID: 24700091 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance - [154]
Hüneburg R, van Bokhorst QNE, Pellisé M et al.. “Artificial intelligence-assisted detection and optical differentiation of colorectal lesions in Lynch syndrome surveillance (CADLY2): a multicentre, open-label, randomised controlled superiority trial.” The lancet. Gastroenterology & hepatology (2026). PMID: 42462747 ↗
L1RCTCited in: 13. Prevention, Screening & Surveillance - [155]
Barda N, Dagan N, Ben-Shlomo Y et al.. “Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.” The New England journal of medicine (2021). PMID: 34432976 ↗
L2OTHERCited in: 13. Prevention, Screening & Surveillance - [156]
Zhang X, Sun S, Fan X et al.. “Thromboembolic events with olanzapine: a systematic review integrating meta-analysis and FAERS database.” Frontiers in cardiovascular medicine (2026). PMID: 41756513 ↗
L1SR_COHORTCited in: 13. Prevention, Screening & Surveillance - [157]
Kim J, Kim TH. “Extended Postoperative Risk of Venous Thromboembolism After Degenerative Spine Surgery: A Nationwide Cohort Study.” Spine (2026). PMID: 42308362 ↗
L2PROSPECTIVE_COHORTCited in: 13. Prevention, Screening & Surveillance - [158]
Yang S, Li G, Li Y et al.. “In-hospital deep vein thrombosis after tibial plateau fractures: incidence, laterality/anatomy, and risk factors in a multicenter retrospective cohort of 3366 patients.” Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology (2026). PMID: 41886203 ↗
L2PROSPECTIVE_COHORTCited in: 13. Prevention, Screening & Surveillance - [159]
Holstein RA, Meyer CH, Herrmann O et al.. “Incidence and Risk Factors for Venous Thromboembolism in Hemodynamically Unstable Pelvic Fractures.” The Journal of surgical research (2026). PMID: 41650792 ↗
L2PROSPECTIVE_COHORTCited in: 13. Prevention, Screening & Surveillance